Floatz logo

Pirtobrutinib

Pirtobrutinib

Zhejiang Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Pirtobrutinib cohort.

Asset / SponsorPhaseRating
Thiotepa
Zhejiang Cancer Hospital
Phase 2CCC

Same molecule, other indications

Pirtobrutinib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →